Cellestia Companies
Cellestia is a clinical stage R&D company that develops innovative therapies to control and modulate pathogenic gene expression in multiple disease areas by selectively inhibiting transcription factors in the cell nucleus. The company's lead compound, CB-103, has successfully treated patients with multi-drug resistant cancers in Phase 2 trials. Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors in oncology, auto-immune, and inflammatory disorders. The company was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland, and is headquartered in Basel, Switzerland.
Industry:
Advanced Longevity (R&D)